Literature DB >> 33651347

Urinary Biomarkers in Tumors: An Overview.

Ilaria Cimmino1, Sara Bravaccini2, Claudio Cerchione3.   

Abstract

Recent reports suggest that urine is a useful noninvasive tool for the identification of urogenital tumors, including bladder, prostate, kidney, and other nonurological cancers. As a liquid biopsy, urine represents an important source for the improvement of new promising biomarkers, a suitable tool to identify indolent cancer and avoid overtreatment. Urine is enriched with DNAs, RNAs, proteins, circulating tumor cells, exosomes, and other small molecules which can be detected with several diagnostic methodologies.We provide an overview of the ongoing state of urinary biomarkers underlying both their potential utilities to improve cancer prognosis, diagnosis, and therapeutic strategy and their limitations.

Entities:  

Keywords:  Biomarker; Exosome; Liquid biopsy; Nonurological cancers; Urine; Urological cancers; miRNA; ucfDNA

Mesh:

Substances:

Year:  2021        PMID: 33651347     DOI: 10.1007/978-1-0716-1354-2_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  59 in total

1.  DNA methylation analysis techniques.

Authors:  Christina Dahl; Per Guldberg
Journal:  Biogerontology       Date:  2003       Impact factor: 4.277

2.  Evaluation of TERT promoter mutations in urinary cell-free DNA and sediment DNA for detection of bladder cancer.

Authors:  Sebastian Stasik; Karsten Salomo; Ulrike Heberling; Michael Froehner; Ulrich Sommer; Gustavo B Baretton; Gerhard Ehninger; Manfred P Wirth; Christian Thiede; Susanne Fuessel
Journal:  Clin Biochem       Date:  2018-12-04       Impact factor: 3.281

Review 3.  GSTP1 methylation in cancer: a liquid biopsy biomarker?

Authors:  Giorgia Gurioli; Filippo Martignano; Samanta Salvi; Matteo Costantini; Roberta Gunelli; Valentina Casadio
Journal:  Clin Chem Lab Med       Date:  2018-04-25       Impact factor: 3.694

Review 4.  The potential use of urine cell free DNA as a marker for cancer.

Authors:  Samanta Salvi; Filippo Martignano; Chiara Molinari; Giorgia Gurioli; Daniele Calistri; Ugo De Giorgi; Vincenza Conteduca; Valentina Casadio
Journal:  Expert Rev Mol Diagn       Date:  2016-11-10       Impact factor: 5.225

Review 5.  Application of liquid biopsy in precision medicine: opportunities and challenges.

Authors:  Junyun Wang; Shuang Chang; Guochao Li; Yingli Sun
Journal:  Front Med       Date:  2017-07-25       Impact factor: 4.592

Review 6.  Personalized medicine: marking a new epoch in cancer patient management.

Authors:  Maria Diamandis; Nicole M A White; George M Yousef
Journal:  Mol Cancer Res       Date:  2010-08-06       Impact factor: 5.852

Review 7.  Genomic medicine: new frontiers and new challenges.

Authors:  Maria D Pasic; Sara Samaan; George M Yousef
Journal:  Clin Chem       Date:  2013-01       Impact factor: 8.327

8.  Methylation-specific sequencing of GSTP1 gene promoter in circulating/extracellular DNA from blood and urine of healthy donors and prostate cancer patients.

Authors:  Olga E Bryzgunova; Evgeniy S Morozkin; Sergey V Yarmoschuk; Valentin V Vlassov; Pavel P Laktionov
Journal:  Ann N Y Acad Sci       Date:  2008-08       Impact factor: 5.691

Review 9.  Liquid biopsy: a step forward towards precision medicine in urologic malignancies.

Authors:  Ashley Di Meo; Jenni Bartlett; Yufeng Cheng; Maria D Pasic; George M Yousef
Journal:  Mol Cancer       Date:  2017-04-14       Impact factor: 27.401

10.  A protocol for urine collection and storage prior to DNA methylation analysis.

Authors:  J Bosschieter; S Bach; I V Bijnsdorp; L I Segerink; W F Rurup; A P van Splunter; I Bahce; P W Novianti; G Kazemier; R J A van Moorselaar; R D M Steenbergen; J A Nieuwenhuijzen
Journal:  PLoS One       Date:  2018-08-24       Impact factor: 3.240

View more
  1 in total

Review 1.  Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.

Authors:  Blanca Trujillo; Anjui Wu; Daniel Wetterskog; Gerhardt Attard
Journal:  Br J Cancer       Date:  2022-06-17       Impact factor: 9.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.